News

ACR's Tender Point Criteria for Fibromyalgia Flawed, Expert Says


 

DESTIN, FLA. — The tender point criteria commonly used to diagnose fibromyalgia are not useful and in fact may even explain why the disease appears to disproportionately affect women, said Daniel Clauw, M.D., speaking at a rheumatology meeting sponsored by Virginia Commonwealth University.

According to the American College of Rheumatology's 1990 classification criteria, patients must have both widespread pain and tenderness in 11 of 18 tender points in order to be diagnosed with fibromyalgia.

Yet “tender points merely represent areas of the body where everyone is more tender,” explained Dr. Clauw, the executive director of the Chronic Pain and Fatigue Research Center at the University of Michigan in Ann Arbor. Fibromyalgia patients and healthy individuals were found to have different thresholds of pain in those tender points. These two groups also had different thresholds of pain in areas not thought to be tender—the forehead and fingernails, for example—as at the recognized tender points. In addition, the cutoff of 11 out of 18 tender points is arbitrary. “We know that tenderness varies a great deal from day to day and week to week, especially in women,” he said.

In clinical practice, many physicians are realizing the arbitrary nature of the diagnostic criteria. The diminished role of tender points represents a shift in the way that they view the disorder. In the past, the disorder was considered a discrete illness with pain and focal areas of tenderness. In more recent years, fibromyalgia has been appreciated as part of a larger continuum, with many somatic symptoms and diffuse tenderness all over the body—not just at tender points.

Tender points are “not even a good way to measure tenderness,” as study findings suggest that the number of tender points correlates better with a patient's general stress than with pain, Dr. Clauw pointed out.

Recommended Reading

TNF Blockers Linked to Severe Skin Reactions : Overall, 25% of patients taking the biologics had a dermatologic event compared with 13% of controls.
MDedge Rheumatology
Data Watch
MDedge Rheumatology
Belimumab, Rituximab Are Next in the Biologic Pipeline for RA
MDedge Rheumatology
TNF Blockers Up Lymphoma Risk : Experts say the study was too small to reach a 'robust conclusion' about such drug-related risks.
MDedge Rheumatology
Out of Africa: Retrovirus Connected to Autoimmune Diseases
MDedge Rheumatology
Review Shows Anti-TNF Treatment Is Best in AS
MDedge Rheumatology
Etanercept Shows Sustained Benefit for Psoriatic Arthritis
MDedge Rheumatology
Treatment With Low-Dose Biologics For Rheumatic Disease Cuts Costs
MDedge Rheumatology
Ankylosing Spondylitis: Risk for Renal Stones
MDedge Rheumatology
Serious Infection Rates Similar Among Biologics
MDedge Rheumatology